Stockholm-based HealthTech startup Loovi has secured €1 million in fresh funding to launch and scale its digital preventive health and longevity platform, following a year of product development and pilot testing.
The round attracted a group of prominent Nordic angel investors, including Susanne Najafi of BackingMinds, Sïmon Saneback of Wellstreet, Jarno Hottinen of Otmore, Emad Zand of Northvolt, Benoit Falenius of Markify, as well as Ultan Miller and Charles Morel.
Founded in 2025 by Joel Grajcer and medical doctor Kevin Najafi, Loovi aims to address what it sees as a structural gap in modern healthcare: the absence of coordinated, data-driven prevention.
From fragmented data to structured prevention
While healthcare systems across Europe generate increasing volumes of health data through lab testing, clinical visits and wearable devices, much of that information remains fragmented and difficult for individuals to interpret.
“The challenge today is not a lack of data, but that people are often left alone with numbers that are difficult to interpret and prioritise,” says Joel Grajcer, co-founder and CEO of Loovi. “At the same time, longevity has become associated with extreme routines that few can realistically maintain. We want to make proactive health management more relatable and sustainable.”
Loovi’s preventive health platform combines blood biomarkers, physical testing, wearable data and lifestyle inputs into a unified digital interface. The system analyses multiple data streams simultaneously to generate a comprehensive health overview and personalised recommendations.
An integrated AI layer helps users understand how different metrics, such as stress, sleep, inflammation markers and metabolic indicators, interact over time. Unlike traditional one-off health check-ups, Loovi is designed as an ongoing programme with continuous monitoring, follow-up and behavioural guidance.
Medical and technical leadership
The founding team blends entrepreneurial and medical expertise. CEO Joel Grajcer leads strategy and growth, while Dr Kevin Najafi, MD and co-founder, brings clinical oversight and medical validation to the platform’s recommendations.
“We want to shift the focus from reacting to diagnoses to acting on early signals,” says Dr Najafi. “There are more health services available than ever before, but few that take the full health picture into account. Our ambition has been to combine medical interpretation, data analysis and human support in one structured system.”
By integrating physician input with technology infrastructure, Loovi aims to ensure that recommendations are medically grounded rather than purely algorithmic.
Positioning within Europe’s preventive HealthTech wave
Loovi’s €1 million raise comes amid growing European investor interest in preventive healthcare platforms. Over 2025 and early 2026, more than €21 million has flowed into startups focused on biomarker analysis, wearable integration and early risk detection across Switzerland, France, Spain and Poland.
While Sweden has not seen a comparable cluster of large preventive HealthTech rounds in the same period, Loovi’s funding positions it within a broader continental trend toward proactive, data-driven healthcare models.
Investors are increasingly backing platforms that aim to reduce long-term healthcare costs by identifying lifestyle-related risks earlier and supporting behavioural change before chronic conditions develop.
Addressing a reactive healthcare model
According to Loovi, much of today’s healthcare infrastructure remains reactive. Early warning signals for metabolic disorders, cardiovascular risk or stress-related conditions are often detected only after symptoms intensify. Even when biomarkers signal elevated risk, sustained follow-up and behavioural support are frequently limited.
Loovi’s model centres on continuity. The platform tracks health metrics longitudinally, adjusts recommendations as new data is added and encourages realistic, incremental lifestyle changes designed to be sustainable.
The company’s mission is to transform longevity from an extreme biohacking niche into an accessible, structured and medically grounded preventive health journey.
Use of funds and next steps
The newly secured capital will be deployed to enhance Loovi’s AI capabilities, expand medical and technical teams and support a broader commercial rollout across Sweden and potentially other European markets.
As preventive health and longevity gain mainstream attention, Loovi is positioning itself as an end-to-end digital platform that connects diagnostics, interpretation and long-term behavioural guidance into one cohesive system.
With growing consumer interest in proactive health management and continued investor appetite for data-driven HealthTech, Loovi’s next phase will test whether structured preventive care can move from niche offering to scalable healthcare model.
Also Read: Can Modal Labs reach a $2.5B valuation as AI inference becomes critical infrastructure?